Previous 10 | Next 10 |
Monthly information regarding the total number of voting rights and total number of shares of the Company as of January 31, 2020 and February 4, 2020 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Pari...
Montrouge, France, February 6, 2020 DBV Technologies Announces Appointment of Pascal Wotling as Chief Technical Operations Officer DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointmen...
Aimmune Therapeutics (NASDAQ: AIMT) won approval from the U.S. Food and Drug Administration for its first drug -- and there are two more important firsts. Aimmune's Palforzia is the first approved drug to treat peanut allergies, and the first approved treatment for any kind of food allergy,...
Aimmune Gets a Boost as FDA Green Signals Allergy Medication Aimmune Therapeutics ( AIMT ) received FDA nod for its peanut allergy medication Palforzia. This orally administered medication aims to mitigate allergic reactions caused by exposure to peanuts. While it is not designed to be an ...
Gainers: Datasea (NASDAQ: DTSS ) +81% . More news on: Datasea Inc., Sintx Technologies, Inc., ReTo Eco-Solutions, Inc., Stocks on the move, , Read more ...
Sundial Growers (NASDAQ: SNDL ) -26% on CEO exit . More news on: Sundial Growers Inc., Briggs & Stratton Corporation, Intelsat S.A., , Stocks on the move, Read more ...
DVB Technologies (NASDAQ: DBVT ) slips 8% premarket on light volume in reaction to its global offering of an aggregate of 7.5M ordinary shares via the following: More news on: DBV Technologies S.A., Healthcare stocks news, Stocks on the move, , Read more ...
Montrouge, France, January 30, 2020 DBV Technologies Announces Pricing of $153.7 million (€139.8 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares DBV Technologies (the “ Company ”) (Euronext: DBV – ISIN: FR001...
Montrouge, France, January 29, 2020 DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares, and Reports December 31, 2019 Cash Position DBV Technologies (the “ Company ”) (Euronext: D...
UK-based Allergy Therapeutics ( OTCPK:AGYTF ) announces the publication of positive data on its peanut allergy vaccine candidate in The Journal of Allergy and Clinical Immunology. More news on: Allergy Therapeutics plc, Aimmune Therapeutics, Inc., DBV Technologies S.A., Healthcare sto...
News, Short Squeeze, Breakout and More Instantly...
DBV Technologies S.A. Company Name:
DBVT Stock Symbol:
NASDAQ Market:
DBV Technologies S.A. Website:
Châtillon, France, July 30, 2024 DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutic...
Châtillon, France, July 30, 2024 DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expecte...
Châtillon, France, July 29, 2024 DBV Technologies to Report Second Quarter 2024 Financial Results and Business Update on July 30, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, toda...